Novotech Acquires US-based Drug Development Consulting Firm, CBR International

SINGAPORE, Jan 12, 2023 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific-centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversight and strategic regulatory operations group. CBR was founded in 2002 as a consultancy company focused on assisting biotechnology and pharma companies navigate FDA requirements from […]

Preventing Strokes and Heart Attacks Doesn't Have to Come with the Risk of Life-threatening Bleeding

FREMONT, CA, Dec 14, 2022 – (ACN Newswire via SEAPRWire.com) – Verseon is delighted to announce that the European Journal of Medicinal Chemistry has published a paper (www.sciencedirect.com/science/article/abs/pii/S0223523422007577) describing the company’s groundbreaking research that led to promising novel drug candidates for cardiovascular disease. Cardiovascular disease is the leading cause of death and disability in the […]

Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials

SYDNEY, AU, Dec 6, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best […]

Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination

TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received notification that Aricept (donepezil hydrochloride), a treatment for Alzheimer’s disease and dementia with Lewy bodies that was discovered and developed in-house, has been granted Category 2* status based on the results of a reexamination of its […]

Hua Medicine’s Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China

SHANGHAI, CHINA, Oct 10, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October […]

Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer

Foster City, CA, and Hangzhou, China, Jul 26, 2022 – (ACN Newswire via SEAPRWire.com) – Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer. In this role, Dr. Wang will lead the drug discovery […]